Calidi Biotherapeutics, Inc. (CLDI) Aandelenanalyse

Bedrijfsoverzicht

Calidi Biotherapeutics, Inc. is a clinical stage immuno-oncology enterprise dedicated to the development of allogeneic stem cell-based and enveloped virus platforms designed to potentiate and deliver oncolytic viruses within the United States. The company operates within the broader Healthcare sector, specifically focusing on the Biotechnology industry, which is characterized by high research and development expenditures and significant regulatory hurdles before products reach the market. As of the latest available data, the company holds a market capitalization of $2.79M and employs a workforce of 29 individuals to execute its strategic initiatives. The combination of a market cap under $3 million and the absence of reported revenue indicates that Calidi Biotherapeutics functions as a micro-cap entity with no current commercial sales, reflecting a stage where value is derived primarily from intellectual property potential rather than operational cash flow.

Financiële gezondheid

The financial statements for the trailing twelve months reveal a revenue figure of N/A, coupled with a net income loss of $-25,579,000 and an EBITDA of $-18,589,000. The substantial gap between the negligible revenue and the significant net income loss highlights a cost structure dominated by research and development expenses and operational overheads rather than sales-related costs. The company generated a free cash flow of $-11,853,875, which signifies a continuous burn rate that consumes internal resources without generating operational surplus. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, indicating that the company has not yet achieved profitability on any of its financial lines due to the lack of revenue generation. In terms of capital structure, the company holds $5.60M in cash against $2.56M in debt, resulting in a debt-to-equity ratio of 68.21 that suggests a balance sheet relying heavily on equity financing rather than leverage. The current ratio stands at 1.59, providing a buffer above 1.0 that indicates adequate short-term liquidity to cover immediate obligations despite the negative earnings position. Return on Equity is reported at -700.6% and Return on Assets at -109.8%, metrics that reveal that management effectiveness is currently measured by the rate of capital erosion rather than value creation.

Waarderingsbeoordeling

The valuation metrics present a challenging picture, with a P/E Ratio (TTM) listed as N/A due to the lack of earnings and a Forward P/E of -0.29. The difference between these figures, where the forward metric is negative, implies that the market is not pricing in immediate earnings recovery but rather valuing the company based on asset backing or future clinical milestones. The price-to-book ratio is 0.50, which indicates that the company's market capitalization is currently trading at half its book value, suggesting the market discounts the asset value or expects significant dilution. Alternative valuation metrics such as the Price to Sales ratio, which is N/A, and the EV/EBITDA of 0.01, suggest that traditional multiple-based comparisons with established peers are not applicable to this pre-revenue biotechnology firm. The stock has experienced extreme volatility over the last year, with a 52-Week High of $19.20 and a 52-Week Low of $0.21. Without a specific current share price provided in the facts, the company's price sits somewhere within this massive range, demonstrating a potential for significant percentage-based movement relative to the low point. The beta value of 1.42 indicates that the stock is expected to be 42% more volatile than the broader market, reflecting the high risk associated with early-stage biotechnology investments.

Growth & Income

Regarding growth metrics, the Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, reflecting the company's status as a pre-commercial entity with no historical earnings data to compare against. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, which explains that all available capital and earnings potential are being retained and reinvested into the clinical trial pipeline rather than distributed to shareholders. The absence of a payout ratio confirms that the company's strategy relies entirely on internal funding or external capital raises to sustain its operations and fund the Phase 1b/2 clinical trial for CLD-101. The overall growth and income profile is defined by a high-risk, zero-income structure where the primary objective is clinical advancement rather than financial return or income generation for investors.